福元醫藥(601089.SH):氯沙坦鉀氫氯噻嗪片未中選第八批國家藥品集採
格隆匯3月30日丨福元醫藥(601089.SH)公佈,公司近日參加了國家組織藥品聯合採購辦公室組織的第八批國家組織藥品集中採購的投標。根據開標結果,公司產品氯沙坦鉀氫氯噻嗪片未中選該次集中採購。
目前,氯沙坦鉀氫氯噻嗪片是公司的核心品種之一。2022年1-9月氯沙坦鉀氫氯噻嗪片銷售收入為2.93億元(未經審計)。該次集中採購未中選將會對公司氯沙坦鉀氫氯噻嗪片未來的銷售情況造成一定的影響,給公司未來發展帶來新的挑戰。
公司氯沙坦鉀氫氯噻嗪片經過多年經營,擁有較高的市場認可度。公司將積極爭取公立醫療機構約定採購量之外的剩餘用量和份額,並加大集採以外市場(包括民營醫院和零售終端等市場)的開發力度。
此外,公司也將加大藥品研發投入力度,優化在研項目結構,提高研發創新能力,推進新產品註冊申報工作,積極尋找和開發新的高附加值產品,逐步減小今後集中採購政策對單品種市場的影響和壓力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.